title: α-Blockers, 5-α-Reductase Inhibitors, Acetylcholine, β3 Agonists, and Phosphodiesterase-5s in Medical Management of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: How Much Do the Different Formulations Actually Matter in the Classes?
abstract: Many monotherapies are currently available to clinically treat and alleviate symptoms of lower urinary tract symptoms secondary to benign prostatic hyperplasia: α-blockers, 5ARIs, PDE5Is, β-3-andrenoceptor agonists, and anticholinergic agents. Current studies have evaluated the effective of these treatments in comparison to other groups or in combination therapies. The current review evaluates the effectiveness of class formulations. Based on the findings, α-blockers, specifically doxazosin and terazosin, were most effective in reducing IPSS scores and peak urinary flow rate, while being most cost-effective. However, further clinical investigations are required to evaluate the clinical implications of different formulations.
authors.affiliation: Department of Urology, Weill Cornell Medicine-New York, Presbyterian Hospital, 425 East 61st Street, 12th Floor, New York, New York 10065, USA. Electronic address: bic9008@med.cornell.edu.
authors.forename: Bilal
authors.initials: B
authors.lastname: Chughtai
authors.affiliation: Department of Urology, Weill Cornell Medicine-New York, Presbyterian Hospital, 425 East 61st Street, 12th Floor, New York, New York 10065, USA.
authors.forename: Dominique
authors.initials: D
authors.lastname: Thomas
authors.affiliation: Department of Urology, Mount Sinai Hospital, 625 Madison Avenue, 59th Street, 2nd Floor, New York, New York 10022, USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Kaplan
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use*; D000109:Acetylcholine / Q000627:therapeutic use*; D058667:Adrenergic beta-3 Receptor Agonists / Q000627:therapeutic use*; D018679:Cholinergic Agonists / Q000627:therapeutic use; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 / Q000627:therapeutic use*; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000188:drug therapy; D014563:Urodynamics / Q000187:drug effects
chemical_list: D058891:5-alpha Reductase Inhibitors; D058667:Adrenergic beta-3 Receptor Agonists; D018679:Cholinergic Agonists; D018727:Muscarinic Antagonists; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D000109:Acetylcholine
keywords: 5-α-Reductase inhibitors (5ARIs); Anticholinergics; Benign prostatic hyperplasia; Lower urinary tract symptoms; Pharmacologic agents; Phosphodiesterase-5 inhibitors; α-Blockers; β-3-Andrenoceptor agonists